InsideArbitrage March 2023 Mid-Month Update – New Position and First Horizon Arbitrage
Over the last three years, I have added several ideas to our watchlist that I liked but wanted to follow for a while or pick
Read More
March 15, 2023
Menu
Over the last three years, I have added several ideas to our watchlist that I liked but wanted to follow for a while or pick
Read More
Our History With B. Riley Instead of focusing on a new idea for our February 2023 mid-month update, I decided to revisit one of our
Read More
Editor’s Note: When we discussed the 1Life Healthcare (ONEM) arbitrage opportunity in the August 2022 Special Situations newsletter the spread on the deal was almost the
Read More
We started the year discussing a basket of “Broken Growth” stocks that had declined anywhere from 50% to 70% from their peaks and looking at
Read More
In our May 2022 Mid-Month Update for Inside Arbitrage Premium and Plus members, we discussed the acquisition of Biohaven Pharmaceuticals by Pfizer (PFE) and wrote
Read More
Summary: Both the Biohaven deal discussed in our May 2022 Mid-Month update and the Bluerock Residential Growth REIT deal discussed in our January 2022 Special
Read More
We discussed the macro economic environment in our Buyback Wednesdays post this Wednesday and the idea I want to discuss for this mid-month update will likely
Read More
The last two months have been a relief for most investors with exposure on the long side with a significant rally off the June 16th
Read More
When we started the month of July, there was speculation about the Fed raising interest rates anywhere from 50 basis points to 75 basis points
Read More
After an intra-day dip into bear market territory in May, the S&P 500 finally entered a bear market earlier this month. We saw some moderation
Read More
Current market conditions have impacted several previously uncorrelated assets that dropped in unison over the last couple of weeks and we have also seen merger
Read More
Considering most of the Inside Arbitrage Model Portfolio companies are yet to report quarterly results, we decided to focus on a new opportunity with recent
Read MoreWe have created a comprehensive group of tools that allows you to estimate the intrinsic value of investments.